A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo

Molecular Vision

Volumn 16, Issue , 2010, Pages 1982-1995

  Xu, Yi ^a   Zhao, Hui ^a   Zheng, Ying ^a   Gu, Qing ^a   Ma, Jianxing ^b   Xu, Xun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MATRIGEL; OXYGEN; SCATTER FACTOR; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHICK; CHORIOALLANTOIS; CHOROID; CONTROLLED STUDY; DISEASE MODEL; ENDOTHELIUM CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RETINA NEOVASCULARIZATION; RETINOPATHY; RHESUS MONKEY;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CHICKENS; CHORIOALLANTOIC MEMBRANE; ENDOTHELIAL CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; MACACA; MICE; MICE, INBRED C57BL; PEPTIDES; PROTEIN STABILITY; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78149480332     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350:48-58.
2. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996; 93:4851-6.
3. Lala-Gitteau E, Majzoub S, Saliba E, Pisella PJ. Epidemiology for retinopathy of prematurity: risk factors in the Tours hospital. J Fr Ophtalmol 2007; 30:366-73.
4. Good WV, Hardy RJ. The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP). Ophthalmology 2001; 108:1013-4.
5. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res 2004; 14:S140-4.
6. Woo JH, Sanjay S, Au Eong KG. The epidemiology of agerelated macular degeneration in the Indian subcontinent. Acta Ophthalmol 2009; 87:262-9.
7. Sapieha P, Hamel D, Shao Z, Rivera JC, Zaniolo K, Joyal JS, Chemtob S. Proliferative retinopathies: angiogenesis that blinds. Int J Biochem Cell Biol 2010; 42:5-12.
8. Neu J, Afzal A, Pan H, Gallego E, Li N, Li Calzi S, Caballero S, Spoerri PE, Shaw LC, Grant MB. The dipeptide Arg-Gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2006; 47:3151-5.
9. Kohno R, Hata Y, Mochizuki Y, Arita R, Kawahara S, Kita T, Miyazaki M, Hisatomi T, Ikeda Y, Aiello LP, Ishibashi T. Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol 2010; 150:223-9.
10. Afzal A, Caballero S, Palii SS, Jurczyk S, Pardue M, Geroski D, Edelhauser H, Hochhaus G, Kim M, Franklin A, Shapiro G, Grant MB. Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole. Brain Res Bull 2010; 81:320-6.
11. Sheikpranbabu S, Haribalaganesh R, Lee KJ, Gurunathan S. Pigment epithelium-derived factor inhibits advanced glycation end products-induced retinal vascular permeability. Biochimie 2010; 92:1040-51.
12. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121:1684-94.
13. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: natural history ROP: ocular outcome at 51/2 years in premature infants with birth weights less than 1251 g. Arch Ophthalmol 2002; 120:595-9.
14. Geisen P, Peterson LJ, Martiniuk D, Uppal A, Saito Y, Hartnett ME. Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Mol Vis 2008; 14:345-57.
15. Pahor D. Visual field loss after argon laser panretinal photocoagulation in diabetic retinopathy: full- versus mildscatter coagulation. Int Ophthalmol 1998; 22:313-9.
16. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005; 293:1509-13.
17. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. N Engl J Med 2004; 351:2805-16.
18. Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol 2006; 17:1399-403.
19. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin formetastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
20. Kim JH, Kim JH, Yu YS, Min BH, Kim KW. Protective effect of clusterin on blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2010; 51:1659-65.
21. Sulochana KN, Ge R. Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des 2007; 13:2074-86.
22. Ruoslahti E, Duza T, Zhang L. Vascular homing peptides with cell-penetrating properties. Curr Pharm Des 2005; 11:3655-60.
23. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have antiangiogenic activity. J Cell Biol 1993; 122:497-511.
24. Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 1999; 55:332-8.
25. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002; 98:682-9.
26. Cattaneo MG, Pola S, Francescato P, Chillemi F, Vicentini LM. Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp Cell Res 2003; 283:230-6.
27. Wickström SA, Alitalo K, Keski-Oja J. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 2004; 279:20178-85.
28. Sulochana KN, Fan H, Jois S, Subramanian V, Sun F, Kini RM, Ge R. Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis. J Biol Chem 2005; 280:27935-48.
29. Kini RM, Caldwell RA, Wu QY, Baumgarten CM, Feher JJ, Evans HJ. Flanking proline residues identify the L-type Ca2+ channel binding site of calciseptine and FS2. Biochemistry 1998; 37:9058-63.
30. Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997; 57:1735-42.
31. Olsson AK, Johansson I, Akerud H, Einarsson B, Christofferson R, Sasaki T, Timpl R, Claesson-Welsh L. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Res 2004; 64:9012-7.
32. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV. Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 2002; 21:4765-77.
33. Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, Kharbanda S, Reimer C, Manfredi M, Dickerson WM, Kalluri R. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J Biol Chem 2001; 276:31959-68.
34. Dixelius J, Olsson AK, Thulin A, Lee C, Johansson I, Claesson-Welsh L. Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein. Cancer Res 2006; 66:2089-97.
35. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002; 2:289-300.
36. Yoshida S, Yamaguchi Y, Itami S, Yoshikawa K, Tabata Y, Matsumoto K, Nakamura T. Neutralization of hepatocyte growth factor leads to retarded cutaneous wound healing associated with decreased neovascularization and granulation tissue formation. J Invest Dermatol 2003; 120:335-43.
37. Grierson I, Heathcote L, Hiscott P, Hogg P, Briggs M, Hagan S. Hepatocyte Growth Factor/Scatter Factor in the eye. Prog Retin Eye Res 2000; 19:779-802.
38. Colombo ES, Menicucci G, McGuire PG, Das A. Hepatocyte growth factor/scatter factor promotes retinal angiogenesis through increased urokinase expression. Invest Ophthalmol Vis Sci 2007; 48:1793-800.
39. Boulton M. A role for hepatocyte growth factor in diabetic retinopathy. Br J Ophthalmol 1999; 83:763-4.
40. Ramos-Lopez M, Hirose T, Lashkari K. Hepatocyte growth factor receptor is selectively activated in the vascular compartment of stage 5 retinopathy of prematurity. Invest Ophthalmol Vis Sci 2003; 44:U112-112.
41. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 2000; 156:1337-44.
42. Lashkari K, Rahimi N, Hirose T, McMeel JW, Kazlauskas A. Hepatocyte growth factor & vascular endothelial growth factor are elevated in subretinal fluid from advanced retinopathy of prematurity. Invest Ophthalmol Vis Sci 1999; 40:S9-9.
43. Hatcher K, Zheng J, Chen SG. Cryptic peptides of the kringle domains preferentially bind to disease-associated prion protein. J Alzheimers Dis 2009; 16:421-31.
44. Buchstein N, Hoffmann D, Smola H, Lang S, Paulsson M, Niemann C, Krieg T, Eming SA. Alternative Proteolytic Processing of Hepatocyte Growth Factor during Wound Repair. Am J Pathol 2009; 174:2116-28.
45. Tomioka D, Maehara N, Kuba K, Mizumoto K, Tanaka M, Matsumoto K, Nakamura T. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 2001; 61:7518-24.
46. Hattori Y, Do WL, Yamada T, Matsumoto K, Nakamura T, Otsuki T, Niikura T, Nukiwa T, Ikeda Y. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells in vitro and in vivo: A mouse model for molecular targeting of angiogenic growth factor. Blood 2004; 104:184A-184A.
47. Kuba K, Matsumoto K, Ohnishi K, Shiratsuchi T, Tanaka M, Nakamura T. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells. Biochem Biophys Res Commun 2000; 279:846-52.
48. Merkulova-Rainon T, England P, Ding S, Demerens C, Tobelem G. The N-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor. J Biol Chem 2003; 278:37400-8.
49. Xin L, Xu R, Zhang Q, Li TP, Gan RB. Kringle 1 of Human Hepatocyte Growth Factor Inhibits Bovine Aortic Endothelial Cell Proliferation Stimulated by Basic Fibroblast Growth Factor and Causes Cell Apoptosis. Biochem Biophys Res Commun 2000; 277:186-90.
50. Shen Z, Yang ZF, Gao Y, Li JC, Chen HX, Liu CC, Poon RT, Fan ST, Luk JM, Sze KH, Li TP, Gan RB, He ML, Kung HF, Lin MC. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Res 2008; 68:404-14.
51. Nie B, Shen Z, Wen JB, Wong OG, Hsueh WD, Huo LF, Kung HF, Jiang B, Lin MC. AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer. Mol Cancer Ther 2008; 7:2855-65.
52. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6:389-95.
53. Merrifield B. Concept and early development of solid-phase peptide synthesis. Methods Enzymol 1997; 289:3-13.
54. Staes E, Rozet E, Ucakar B, Hubert P, Préat V. Validation of a method for the quantitation of ghrelin and unacylated ghrelin by HPLC. J Pharmaceut Biomed 2010; 51:633-9.
55. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006; 70:146-57.
56. Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T, Hinuma S, Baba A. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 2004; 325:395-400.
57. Yu WZ, Zou H, Li XX, Yan Z, Dong JQ. Effects of the phosphatidylinositol 3-kinase inhibitor in a mouse model of retinal neovascularization. Ophthalmic Res 2008; 40:19-25.
58. Sulochana KN, Fan H, Jois S, Subramanian V, Sun F, Kini RM, Ge R. Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis. J Biol Chem 2005; 280:27935-48.
59. Rivera-Lopez CM, Tucker AL, Lynch KR. Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis 2008; 11:301-10.
60. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. Oxygen-Induced Retinopathy in the Mouse. Invest Ophthalmol Vis Sci 1994; 35:101-11.
61. Parsons-Wingerter P, Chandrasekharan UM, McKay TL, Radhakrishnan K, DiCorleto PE, Albarran B, Farr AG. VEGF165-induced phenotypic switch from increased vessel densityto increased vessel diameter and increased endothelial NOS activity. Microvasc Res 2006; 72:91-100.
62. Carneiro A, Falcao M, Pirraco A, Milheiro-Oliveira P, Falcao-Reis F, Soares R. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res 2009; 88:522-7.
63. Mayo KH, van der Schaft DW, Griffioen AW. Designed ß-sheet peptides that inhibit proliferation and induce apoptosis in endothelial cells. Angiogenesis 2001; 4:45-51.
64. Ottino P, Finley J, Rojo E, Ottlecz A, Lambrou GN, Bazan HE, Bazan NG. Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: involvement of cytosolic phospholipase A2 activity. Mol Vis 2004; 17:341-50.
65. Yu LL, Wu XM, Cheng ZY, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N. Interaction between bevacizumab and murine VEGF-A: A reassessment. Invest Ophthalmol Vis Sci 2008; 49:522-7.
66. Talavera-Adame D, Xiong YZ, Zhao T, Arias AE, Sierra-Honigmann MR, Farkas DL. Quantitative and morphometric evaluation of the angiogenic effects of leptin. J Biomed Opt 2008; 13:064017.
67. Antosova Z, Mackova M, Kral V, Macek T. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol 2009; 27:628-35.
68. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003; 22:721-48.